MetaCap

Immunovant (IMVT) vs Kodiak Sciences (KOD)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Kodiak Sciences (KOD) has outperformed Immunovant (IMVT) over the past year, gaining 367.8% versus a gain of 40.6%. Over five years, IMVT leads with a +308.9% price change compared with +3.0% for KOD. Immunovant is the larger company by market cap ($6.57 billion vs $6.35 billion), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

IMVT+40.64%KOD+367.84%
+457%+216%-24%
Nov 21, 20251 yearNov 20, 2026
IMVT+286.50%KOD-1.51%
+467%+171%-125%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

IMVT versus KOD key metrics
MetricIMVTKOD
Share price$31.77$97.17
Market cap$6.57B$6.35B
1-day change-2.31%-0.75%
YTD return+24.98%+247.53%
1-year return+40.64%+367.84%
5-year return+308.88%+3.04%
EPS (TTM)$-2.56$-4.08
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-505.61M$-229.97M
52-week high$45.42$112.79
52-week low$21.93$20.38
Distance from 52-week high-30.05%-13.85%
Analyst consensusbuystrong_buy
Avg. price target upside+53.07%+33.27%
Average volume1.42M1.77M
Shares outstanding206.95M65.40M
Employees315144
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • KOD has outperformed IMVT by 327.2 percentage points over the past year.

About Immunovant

IMVT stock →

Immunovant, Inc., a clinical-stage immunology company, develops targeted therapies to meet the needs of people with autoimmune diseases. It develops IMVT-1402, a human monoclonal antibody that inhibits neonatal fragment crystallizable receptor for graves' disease, rheumatoid arthritis, sjögren's disease, cutaneous lupus erythematosus disease, myasthenia gravis, and chronic inflammatory demyelinating polyneuropathy.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 315 employees

About Kodiak Sciences

KOD stock →

Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor (VEGF) antibody biopolymer that has complete Phase 3 clinical study to treat high prevalence retinal vascular diseases; and in Phase 3 clinical study for the treatment of diabetic retinopathy, wet age-related macular degeneration (AMD), retinal vein occlusion, and diabetic macular edema, as well as in Phase 2/3 clinical study to treat wet AMD.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 144 employees

IMVT vs KOD FAQ

Which is bigger, Immunovant or Kodiak Sciences?

Immunovant (IMVT) is larger, with a market capitalization of $6.57B compared with $6.35B for Kodiak Sciences (KOD).

Which stock has performed better over the past year, IMVT or KOD?

KOD returned +367.84% over the past 12 months, compared with +40.64% for IMVT (price return, excluding dividends). Past performance does not predict future results.

Are Immunovant and Kodiak Sciences in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons